MapLight Therapeutics, Inc. has 9 Schedule 13D or 13G filings on record since 2025-11-04. 4 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Catalyst4, Inc. | 49.9% | 27,536,011 | SCHEDULE 13D/A, 2026-08-18 | 2026-08-14 |
| T. Rowe Price Investment Management, Inc. | 7.4% | 3,137,558 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 7.1% | 3,226,400 | SCHEDULE 13G, 2026-02-17 | 2025-12-31 |
| Nan Fung Group Holdings Limited | 5.5% | 2,915,874 | SCHEDULE 13G, 2026-08-20 | 2026-08-13 |
| Novo Holdings A/S | 4.9% | 2,086,622 | SCHEDULE 13D/A, 2026-07-31 | 2026-07-30 |
Purpose of Transaction (Item 4)
Catalyst4, Inc.
Item 4 of the Original Schedule 13D is hereby amended as follows: On August 13, 2026, Catalyst entered into a securities purchase agreement, which is filed as Exhibit 99.4 to this Statement ("Securities Purchase Agreement") with the Issuer, pursuant to which the Catalyst agreed to purchase an aggregate of (i) 4,400,000 shares of the Issuer's voting common stock and (ii) accompanying pre-funded warrants to purchase up to 2,928,686 shares of voting common stock (the "Pre-Funded Warrants"), which is filed as Exhibit 99.5 to this Statement (the "PIPE Offering"). The purchase price per share of voting common stock is $11.38 per share (the "Purchase Price") and the purchase price for the Pre-Funded Warrants is the Purchase Price minus $0.0001 per share underlying the Pre-Funded Warrants. The PIPE Offering closed on August 14, 2026. The Pre-Funded Warrants are exercisable at any time and do not expire until exercised in full, however, the Pre-Funded Warrants may not be exercised if the aggregate number of shares of voting common stock beneficially owned by the Reporting Person immediately following such exercise would exceed 49.99%. Accordingly, only 2,229,322 of the Pre-Funded Warrants are included in the beneficial ownership reported by any of the Reporting Persons on their respective cover pages because they are exercisable within 60 days of August 14, 2026.Item 4 of the SCHEDULE 13D/A filed 2026-08-18
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-04 | Novo Holdings A/S | 8.4% | SCHEDULE 13D |
| 2025-11-20 | Catalyst4, Inc. | 45.1% | SCHEDULE 13D |
| 2026-02-17 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 7.1% | SCHEDULE 13G |
| 2026-02-17 | T. Rowe Price Investment Management, Inc. | 6.2% | SCHEDULE 13G |
| 2026-05-15 | T. Rowe Price Investment Management, Inc. | 7.4% | SCHEDULE 13G/A |
| 2026-07-31 | Novo Holdings A/S | 4.9% | SCHEDULE 13D/A |
| 2026-08-03 | Catalyst4, Inc. | 47.9% | SCHEDULE 13D/A |
| 2026-08-18 | Catalyst4, Inc. | 49.9% | SCHEDULE 13D/A |
| 2026-08-20 | Nan Fung Group Holdings Limited | 5.5% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for MapLight Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.